Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 16, 2008

MitoSciences Secures University of Oregon mAbs Related to Mitochondrial Research for $4.6M

  • MitoSciences will pay $4.6 million over 10 years for a suite of biotechnology innovations from the University of Oregon (UO). Under the exclusive licence arrangement, MitoSciences will also pay UO royalties on patent-related sales.

    The agreement centers on a portfolio of mAbs that MitoSciences is using to develop cell-based drug toxicity screening tests and multiplexing assays to generate mitochondrial protein biomarkers for diagnostics and personalized medicine. The antibodies are also sold individually and in kits to the life science research market.

    Along with the antibody hybridomas and other biological assets, UO will also transfer several commercial distribution agreements through which it previously delivered antibodies to life science researchers. MitoSciences will have exclusive commercialization rights for the complete portfolio of transferred biological assets, plus an exclusive license under several university patents that cover the use of mAbs that recognize mitochondrial antigens.

    The deal with UO along with others such as the recently inked collaboration with Invitrogen and agreements yet to be announced will strengthen MitoSciences’ focus on developing mitochondrial research tools.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »